About: 1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery
Source	Elsevier; PMC
abstract	The past 10 years has seen the rise of large numbers of small- and medium-size enterprises (SMEs) engaging in some or many of the aspects of drug research. Few of these companies have been able to take candidate drugs to market due to development costs not being met by funding opportunities, but those companies that have been able to challenge traditional big pharma in the marketplace. Most SMEs have instead supplied traditional pharma with pipeline candidate drugs, either by licensing them or by the large companies actually acquiring the whole of the SME which owns the intellectual property. Many other companies engage in providing traditional big pharma or other SMEs with technologies and services. Hundreds of such companies have arisen, many clustered around centres of academic excellence on the coasts of the USA, or in certain regions in Europe and Asia – such clustering of scientific prowess has changed the location of where even big pharma tends to perform its research. By 2006, a large proportion (but generally less than 50%) of new drugs could be track to an origin in an SME, trends indicate that the proportion will rise even though the common prediction that large pharma will abandon internal research in favour of in-licensing from SMEs remains far from reality.
has issue date	2007-12-31(xsd:dateTime)
bibo:doi	10.1016/b0-08-045044-x/00016-x
has license	els-covid
sha1sum (hex)	bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d
schema:url	https://doi.org/10.1016/b0-08-045044-x/00016-x
resource representing a document's title	1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery
has PubMed Central identifier	PMC7152157
schema:publication	Comprehensive Medicinal Chemistry II
resource representing a document's body	covid:bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d#body_text
is schema:about of	named entity 'recombinant tissue plasminogen activator' named entity 'private corporation' named entity 'Germany' named entity 'UK Medical Research Council's' named entity 'polymerization inhibitor' named entity 'Emtricitabine' named entity 'Ion channel' named entity 'chronic granulomatous disease' named entity 'drug discovery' named entity 'Filgrastim' named entity 'infectious diseases' named entity 'drug discovery' named entity 'genetics' named entity 'Weinberg Group' named entity 'privately held' named entity 'Celltech' named entity 'San Francisco Bay area' named entity 'biochemistry' named entity 'Biotech' named entity 'private company' named entity 'drug discovery' named entity 'symptom' named entity 'kinase' named entity 'Amgen' named entity 'CD80' named entity 'oncology' named entity 'monoclonal antibody' named entity 'Biotechnology' named entity 'heart failure' named entity 'B-cell' named entity 'Paget's disease' named entity 'venture capitalists' named entity 'Omalizumab' named entity 'Evotec' named entity 'San Diego' named entity 'platelet-derived growth factor' named entity 'drug discovery' named entity 'plaque psoriasis' named entity 'researches and develops' named entity 'adalimumab' named entity 'molecule' named entity 'bronchial asthma' named entity 'St Mary's Hospital' named entity 'insomnia' named entity 'SME' named entity 'hematology' named entity 'Dornase alfa' named entity 'psoriasis' named entity 'biotechnology' named entity 'human monoclonal antibody' named entity 'San Francisco' named entity 'small-molecule' named entity 'asthma' named entity 'norepinephrine' named entity 'Lead Optimization' named entity 'HIV infection' named entity 'Bayer' named entity 'Ibritumomab tiuxetan' named entity 'Medivir' named entity 'Paris' named entity 'Research Institute' named entity 'Finland' named entity 'mRNA' named entity 'Canada' named entity 'chemoattractant' named entity 'Biogen Idec' named entity 'synthetic peptide' named entity 'Los Angeles' named entity 'Galapagos' named entity 'biotech' named entity 'SMEs' named entity 'HIV infection' named entity 'drug discovery' named entity 'small-molecule' named entity 'enoximone' named entity 'heart disease' named entity 'cell lines' named entity 'SME' named entity 'Drug Discovery' named entity 'Novartis' named entity 'insomnia' named entity 'pharmaceutical drug' named entity 'Montreal' named entity 'Institute of Molecular Medicine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software